These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7787424)

  • 1. High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion.
    Constantine KL; Friedrichs MS; Detlefsen D; Nishio M; Tsunakawa M; Furumai T; Ohkuma H; Oki T; Hill S; Bruccoleri RE
    J Biomol NMR; 1995 Apr; 5(3):271-86. PubMed ID: 7787424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.
    Lin PF; Samanta H; Bechtold CM; Deminie CA; Patick AK; Alam M; Riccardi K; Rose RE; White RJ; Colonno RJ
    Antimicrob Agents Chemother; 1996 Jan; 40(1):133-8. PubMed ID: 8787894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I.
    Detlefsen DJ; Hill SE; Volk KJ; Klohr SE; Tsunakawa M; Furumai T; Lin PF; Nishio M; Kawano K; Oki T
    J Antibiot (Tokyo); 1995 Dec; 48(12):1515-7. PubMed ID: 8557614
    [No Abstract]   [Full Text] [Related]  

  • 4. MS-271, a novel inhibitor of calmodulin-activated myosin light chain kinase from Streptomyces sp.--II. Solution structure of MS-271: characteristic features of the "lasso' structure.
    Katahira R; Yamasaki M; Matsuda Y; Yoshida M
    Bioorg Med Chem; 1996 Jan; 4(1):121-9. PubMed ID: 8689232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection.
    De Clercq E
    Med Res Rev; 2000 Sep; 20(5):323-49. PubMed ID: 10934347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
    Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
    Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
    Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles.
    Schibli DJ; Montelaro RC; Vogel HJ
    Biochemistry; 2001 Aug; 40(32):9570-8. PubMed ID: 11583156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin.
    Gordon LM; Curtain CC; McCloyn V; Kirkpatrick A; Mobley PW; Waring AJ
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1145-56. PubMed ID: 8312056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and structure determination of a new lasso peptide specialicin based on genome mining.
    Kaweewan I; Hemmi H; Komaki H; Harada S; Kodani S
    Bioorg Med Chem; 2018 Dec; 26(23-24):6050-6055. PubMed ID: 30448257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of solution structure and lipid micelle location of an engineered membrane peptide by using one NMR experiment and one sample.
    Wang G
    Biochim Biophys Acta; 2007 Dec; 1768(12):3271-81. PubMed ID: 17905196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
    Pritsker M; Jones P; Blumenthal R; Shai Y
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7287-92. PubMed ID: 9636141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
    AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on mollicutes (wall-less bacteria) of synthetic peptides comprising a signal peptide or a membrane fusion peptide, and a nuclear localization sequence (NLS) -- a comparison with melittin.
    Béven L; Chaloin L; Vidal P; Heitz F; Wróblewski H
    Biochim Biophys Acta; 1997 Oct; 1329(2):357-69. PubMed ID: 9371427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain.
    Jaroniec CP; Kaufman JD; Stahl SJ; Viard M; Blumenthal R; Wingfield PT; Bax A
    Biochemistry; 2005 Dec; 44(49):16167-80. PubMed ID: 16331977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid-state nuclear magnetic resonance evidence for parallel and antiparallel strand arrangements in the membrane-associated HIV-1 fusion peptide.
    Yang J; Weliky DP
    Biochemistry; 2003 Oct; 42(40):11879-90. PubMed ID: 14529300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of fusion inhibitors in HIV infection.
    De Clercq E
    Drugs R D; 1999 Nov; 2(5):321-31. PubMed ID: 10728472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.
    Jiang S; Lin K; Strick N; Neurath AR
    Biochem Biophys Res Commun; 1993 Sep; 195(2):533-8. PubMed ID: 8373393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.